» Articles » PMID: 22343321

Cancer Stem-like Cells Contribute to Cisplatin Resistance and Progression in Bladder Cancer

Overview
Journal Cancer Lett
Specialty Oncology
Date 2012 Feb 21
PMID 22343321
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

A variety of cancer stem-like cells (CSCs) have been shown to be responsible for cancer tumorigenicity, relapse and metastasis. Despite several reports demonstrating the presence of CSCs in human bladder cancer, their identities are still under debate, and few studies have examined their roles in cisplatin resistance and related tumor progression. In this study, a subpopulation of CSCs was enriched following cisplatin selection from the bladder cell line T24. The cisplatin-resistant T24 cells displayed a greater self-renewal capacity as demonstrated by higher levels of sphere formation and stem cell marker expression, contained a larger proportion of side population cells and exhibited higher tumorigenicity. They also possessed epithelial-mesenchymal transition characteristics. Furthermore, a strong correlation between the levels of Bmi1 and Nanog expression and the degree of malignancy of urothelial cell carcinomas tissues was observed. We provide the first direct evidence that CSC-like cells exist in the population of cisplatin-resistant bladder cancer cells and may play a role in the progression and drug resistance of bladder cancer.

Citing Articles

Cancer stem-like cells stay in a plastic state ready for tumor evolution.

Xu J, Zhang H, Nie Z, He W, Zhao Y, Huang Z Neoplasia. 2025; 61:101134.

PMID: 39919692 PMC: 11851212. DOI: 10.1016/j.neo.2025.101134.


Integrative Single Cell Atlas Revealed Intratumoral Heterogeneity Generation from an Adaptive Epigenetic Cell State in Human Bladder Urothelial Carcinoma.

Xiao Y, Jin W, Qian K, Ju L, Wang G, Wu K Adv Sci (Weinh). 2024; 11(24):e2308438.

PMID: 38582099 PMC: 11200000. DOI: 10.1002/advs.202308438.


Sulforaphane and bladder cancer: a potential novel antitumor compound.

Zuo M, Chen H, Liao Y, He P, Xu T, Tang J Front Pharmacol. 2023; 14:1254236.

PMID: 37781700 PMC: 10540234. DOI: 10.3389/fphar.2023.1254236.


Cancer-Associated Fibroblast-Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer.

Liang T, Tao T, Wu K, Liu L, Xu W, Zhou D Adv Sci (Weinh). 2023; 10(31):e2303230.

PMID: 37743226 PMC: 10625065. DOI: 10.1002/advs.202303230.


Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic Biomarkers in Bladder Cancer.

Chin F, Chan S, Veerakumarasivam A Diagnostics (Basel). 2023; 13(16).

PMID: 37627900 PMC: 10453580. DOI: 10.3390/diagnostics13162641.